Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie som sammenligner Zanubrutinib + Rituximab versus Bendamustine + Rituximab hos deltakere med ubehandlet mantelcellelymfom (MANGROVE)

25. september 2026 oppdatert av: BeOne Medicines

En fase 3 randomisert, åpen, multisenterstudie som sammenligner Zanubrutinib (BGB-3111) Plus Rituximab versus Bendamustine Plus Rituximab hos pasienter med tidligere ubehandlet mantelcellelymfom som ikke er kvalifisert for stamcelletransplantasjon

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Studietype

Intervensjonell

Registrering (Faktiske)

510

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2605
        • Canberra Hospital
    • New South Wales
      • Concord, New South Wales, Australia, 2139
        • Concord Repatriation General Hospital
      • Cudgen, New South Wales, Australia, 2487
        • The Tweed Valley Hospital
      • Darlinghurst, New South Wales, Australia, 2010
        • Saint Vincents Hospital Sydney
      • Gosford, New South Wales, Australia, 2250
        • Gosford Hospital
      • Waratah, New South Wales, Australia, 2298
        • Calvary Mater Newcastle
    • Queensland
      • Birtinya, Queensland, Australia, 4575
        • Sunshine Coast Hospital and Health Service
      • South Brisbane, Queensland, Australia, 4101
        • Icon Cancer Foundation
    • South Australia
      • Bedford PK, South Australia, Australia, 5042
        • Flinders Medical Centre
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Royal Hobart Hospital
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Monash Health
      • Fitzroy, Victoria, Australia, 3065
        • St Vincents Hospital Melbourne
      • Frankston, Victoria, Australia, 3199
        • Peninsula Private Hospital
      • Geelong, Victoria, Australia, 3220
        • Barwon Health the Geelong Hospital
    • Western Australia
      • Perth, Western Australia, Australia, 6000
        • Royal Perth Hospital
      • Bruges, Belgia, 8000
        • Az Sint Jan Brugge
      • Brussels, Belgia, 1090
        • Universitair Ziekenhuis Brussel
      • Edegem, Belgia, 2650
        • Uz Antwerpen
      • Kortrijk, Belgia, 8500
        • Az Groeninge Campus Loofstraat
      • Liège, Belgia, 4000
        • Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
      • Yvoir, Belgia, 5530
        • Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8M2
        • The Ottawa Hospital
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Ciusss de Lestrie Chus
    • California
      • Orange, California, Forente stater, 92868
        • Chao Family Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Rush University Medical Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215-5400
        • Beth Israel Deaconess Medical Center (Bidmc)
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan Health System
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89169
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine At Mount Sinai
      • Westbury, New York, Forente stater, 11590
        • Clinical Research Alliance, Inc
    • Oregon
      • Portland, Oregon, Forente stater, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • West Penn Hospital
    • Texas
      • Houston, Texas, Forente stater, 77030-4009
        • The University of Texas Md Anderson Cancer Center
      • Lubbock, Texas, Forente stater, 79410
        • Joe Arrington Cancer Research and Treatment Center
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Seattle Cancer Care Alliance
      • Bordeaux, Frankrike, 33076
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • Brest, Frankrike, 29200
        • Chru de Brest Hospital Morvan
      • Dijon, Frankrike, J4V 2H1
        • Chu Dijon
      • Grenoble, Frankrike, 38043
        • Chu Grenoble Alpes
      • Le Mans, Frankrike, 72037
        • Centre Hospitalier Le Mans
      • Lille, Frankrike, 59000
        • Hopital Claude Huriez Chu Lille
      • Marseille, Frankrike, 13009
        • Institut Paoli Calmettes
      • Nantes, Frankrike, 44093
        • Centre Hospitalier Universitaire Nantes Hotel Dieu
      • Paris, Frankrike, 75005
        • Institut Curie
      • Paris, Frankrike, 75015
        • Necker University Hospital
      • PierreBenite, Frankrike, 69495
        • Chu Hopital Lyon Sud
      • Poitiers, Frankrike, 86000
        • Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
      • Quimper, Frankrike, 29000
        • Ch Cornouaille
      • Toulouse, Frankrike, 31059
        • Iuc Toulouse Oncopole
      • Cork, Irland, t12DC4A
        • Cork University Hospital
      • Dublin, Irland, D7
        • Mater Misericordiae University Hospital
      • Dublin, Irland, D8
        • St Jamess Hospital
      • Galway, Irland, H91 YR71
        • University Hospital Galway
      • Limerick, Irland, V94F858
        • University Hospital Limerick
      • Waterford, Irland, X91 ER8E
        • University Hospital Waterford
      • Alessandria, Italia, 15121
        • Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
      • Bologna, Italia, 40138
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Genova, Italia, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Milan, Italia, 20162
        • Niguarda Cancer Center Division of Hematology
      • Novara, Italia, 28100
        • Aou Maggiore Della Carita
      • Palermo, Italia, 90146
        • Aoor Villa Sofia Cervello
      • Pisa, Italia, 56126
        • Aou Pisana, Stabilimento Di Santa Chiara
      • Ravenna, Italia, 48121
        • Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
      • Reggio Emilia, Italia, 42123
        • Azienda Unita Sanitaria Locale Irccs
      • Roma, Italia, 00161
        • Universita Degli Studi La Sapienza
      • Siena, Italia, 53100
        • Aou Senese Policlinico Santa Maria Alle Scotte
      • Torino, Italia, 10126
        • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
      • Verona, Italia, 37142
        • University of Verona
      • Yokohama, Japan, 221-0855
        • Yokohama Municipal Citizens Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 460-0001
        • National Hospital Organization Nagoya Medical Center
      • Toyohashi, Aichi-ken, Japan, 441-8570
        • Toyohashi Municipal Hospital
    • Chiba
      • Chiba, Chiba, Japan, 260-8717
        • Chiba Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Japan, 830-0011
        • Kurume University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japan, 730-8619
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 241-8515
        • Kanagawa Cancer Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 860-0008
        • National Hospital Organization Kumamoto Medical Center
    • Kyoto
      • Kyoto, Kyoto, Japan, 602-8566
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, Japan, 980-8574
        • Tohoku University Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Japan, 710-8602
        • Kurashiki Central Hospital
      • Okayama, Okayama-ken, Japan, 701-1192
        • National Hospital Organization Okayama Medical Center
    • Osaka
      • Osaka, Osaka, Japan, 545-8586
        • Osaka Metropolitan University Hospital
      • Osakashi, Osaka, Japan, 543-8555
        • Osaka Red Cross Hospital
    • Tokyo
      • Chuoku, Tokyo, Japan, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Tokyo, Japan, 113-8519
        • Tokyo Medical and Dental University Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100044
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, Kina, 100050
        • Beijing Friendship Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, Kina, 350001
        • Fujian Medical University Union Hospital
      • Quanzhou, Fujian, Kina, 362000
        • Quanzhou First Affliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Guangdong Provincial Peoples Hospital
      • Guangzhou, Guangdong, Kina, 510515
        • Nanfang Hospital of Southern Medical University
      • Guangzhou, Guangdong, Kina, 510060
        • Sun Yat Sen University Cancer Center
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150000
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, Kina, 450000
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, Kina, 410013
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Jiangsu Province Hospital
      • Nanjing, Jiangsu, Kina, 210008
        • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
      • Xuzhou, Jiangsu, Kina, 221000
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • The First Affiliated Hospital of Nanchang University Branch Donghu
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • The First Hospital of Jilin University
      • Changchun, Jilin, Kina, 130021
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Kina, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200000
        • Fudan University Shanghai Cancer Center
      • Shanghai, Shanghai Municipality, Kina, 200120
        • Shanghai East Hospital
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • West China Hospital, Sichuan University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin, Tianjin Municipality, Kina, 300020
        • Institute of Hematology and Hospital of Blood Disease
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 830000
        • Affiliated Cancer Hospital of Xinjiang Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, Kina, 310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, Kina, 315000
        • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
      • Goes, Nederland, 4462 RA
        • Admiraal de Ruijter Ziekenhuis
      • Groningen, Nederland, 9713 GZ
        • University of Medical Center Groningen (Umcg)
      • Nieuwegein, Nederland, 3435 CM
        • St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
      • Nijmegen, Nederland, 6525 GA
        • Albert Schweitzer Ziekenhuis
      • Rotterdam, Nederland, 3015 GD
        • Erasmus Mc
      • The Hague, Nederland, 2545 CH
        • Hagaziekenhuis
      • Christchurch, New Zealand, 8011
        • Christchurch Hospital (Canterbury Health Laboratories)
      • Tauranga, New Zealand, 3112
        • Tauranga Hospital
      • Bydgoszcz, Polen, 85-168
        • Szpital Uniwersytecki Nr Im Dr Jana Biziela
      • Chorzów, Polen, 41-503
        • Silesian Healthy Blood Clinic
      • Gdansk, Polen, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Gdask, Polen, 80-219
        • Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
      • Gdynia, Polen, 81-519
        • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
      • Krakow, Polen, 30-727
        • Pratia McM Krakow
      • Legnica, Polen, 59-220
        • Wojewodzki Szpital Specjalistyczny W Legnicy
      • Lodz, Polen, 93-510
        • Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Polen, 20-090
        • Centrum Onkologii Ziemi Lubelskiej
      • Warsaw, Polen, 02-776
        • Instytut Hematologii I Transfuzjologii W Warszawie
      • Wałbrzych, Polen, 58-309
        • Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
      • Wroclaw, Polen, 50-556
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Lisbon, Portugal, 1099-023
        • Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
      • Lisbon, Portugal, 1649-035
        • Chuln Hospital de Santa Maria
      • Porto, Portugal, 4099-001
        • Centro Hospitalar Universitario Porto
      • Porto, Portugal, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
      • Bucharest, Romania, 022328
        • Institutul Clinic Fundeni
      • Iași, Romania, 700483
        • Institutul Regional de Oncologie Iasi
      • Moscow, Russland, 142770
        • Gbuz Mmcc Kommunarka Dzm
    • Moscow
      • Moscow, Moscow, Russland, 125284
        • Clinical Hospital, Sp Botkin
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Russland, 191024
        • Fgu Russian Scientific Research Institute of Hematology and Transfusiology
      • Saint Petersburg, Sankt-Peterburg, Russland, 194291
        • Leningrad Regional Clinic and Hospital
      • Barcelona, Spania, 08035
        • Hospital Universitario Vall Dhebron
      • Barcelona, Spania, 08916
        • Ico Hug Trias I Pujol
      • Barcelona, Spania, 08908
        • Institut Catala Doncologia
      • Girona, Spania, 17007
        • Ico Girona
      • Madrid, Spania, 28046
        • Hospital Universitario La Paz
      • Madrid, Spania, 28040
        • Start Madrid Fundacion Jimenez Diaz
      • Madrid, Spania, 28033
        • Md Anderson Cancer Center Madrid Spain
      • Madrid, Spania, 28009
        • Hospital Universitario Gregorio Maranon
      • Málaga, Spania, 29010
        • Hospital Regional Universitario de Malaga
      • Seville, Spania, 41013
        • Hospital Universitario Virgen Del Rocio
      • Abergavenny, Storbritannia, NP7 7EG
        • Aneurin Bevan University Health Board
      • Birmingham, Storbritannia, B9 5SS
        • Birmingham Heartlands Hospital
      • Dudley, Storbritannia, DY1 2HQ
        • Russells Hall Hopsital
      • Sutton, Storbritannia, SM2 5PT
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Tainan, Taiwan, 736
        • Chi Mei Hospital Liouying
      • Taipei, Taiwan, 114
        • Tri Service General Hospital
      • Ankara, Tyrkia (Türkiye), 06620
        • Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
      • Ankara, Tyrkia (Türkiye), 6500
        • Gazi University
      • Ankara, Tyrkia (Türkiye), 06700
        • Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
      • Edirne, Tyrkia (Türkiye), 22030
        • Tr Trakya University Health Research and Application Center (Hospital)
      • Istanbul, Tyrkia (Türkiye), 34365
        • Vkv American Hospital
      • Mersin, Tyrkia (Türkiye), 33000
        • Mersin Universitesi Tip Fakultesi Hastanesi
      • Cologne, Tyskland, 50937
        • Uniklinik Koln (Aor)
      • Heidelberg, Tyskland, 69120
        • Universitatsklinikum Heidelberg
      • Munich, Tyskland, 81377
        • Dept of Medicine Iii, University Hospitallmu
      • Ulm, Tyskland, 89081
        • Universitaetsklinikum Ulm, Innere Medizin Iii
      • Wuppertal, Tyskland, 42283
        • Petrus Krankenhaus Wuppertal
      • Cherkasy, Ukraina, 18009
        • Cherkasy Regional Oncology Dispensary
      • Dnipro, Ukraina, 49102
        • Municipal Non Profit Enterprise City Clinical Hospital
      • Kiev, Ukraina, 3022
        • National Cancer Institute
      • Lviv, Ukraina, 79044
        • Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department
      • Linz, Østerrike, 4020
        • Ordensklinikum Linz Gmbh Elisabethinen
      • Salzburg, Østerrike, 5020
        • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
      • Vienna, Østerrike, 1090
        • Medical University Vienna Oncology

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

60 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  1. ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
  2. Histologically confirmed diagnosis of MCL
  3. No prior systemic treatments for MCL
  4. Measurable disease by CT/MRI
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  6. Adequate marrow and organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
  3. Clinically significant cardiovascular disease
  4. History of severe bleeding disorder
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  6. Active fungal, bacterial and/or viral infection requiring systemic therapy
  7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A: zanubrutinib plus rituximab

Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.

Administered as two 80 mg capsules by mouth twice a day

Andre navn:
  • Brukinsa
  • BGB-3111

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Aktiv komparator: Arm B: bendamustine plus rituximab

Participants will receive bendamustine plus rituximab, followed by observation.

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free survival (PFS) determined by independent central review
Tidsramme: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
PFS by investigator assessment
Tidsramme: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years
Overall response rate (ORR)
Tidsramme: Up to approximately 7 years

ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment.

Up to approximately 7 years
Duration of response (DOR)
Tidsramme: Up to approximately 7 years

DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first.

Up to approximately 7 years
Overall survival (OS)
Tidsramme: Up to approximately 7 years

OS is defined as the time from randomization to the date of death due to any reason.

Up to approximately 7 years
Time to Response (TTR)
Tidsramme: Up to approximately 7 years

TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response.

Up to approximately 7 years
Rate of complete response (CR) or complete metabolic response
Tidsramme: Up to approximately 7 years

Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment.

Up to approximately 7 years
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
Tidsramme: Up to approximately 7 years

EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

Up to approximately 7 years
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Tidsramme: Up to approximately 7 years

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

Up to approximately 7 years
Number of participants with adverse events and serious adverse events
Tidsramme: Up to approximately 7 years

Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings.

Up to approximately 7 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Study Director, BeOne Medicines

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. august 2019

Primær fullføring (Faktiske)

27. april 2026

Studiet fullført (Antatt)

30. september 2031

Datoer for studieregistrering

Først innsendt

27. juni 2019

Først innsendt som oppfylte QC-kriteriene

27. juni 2019

Først lagt ut (Faktiske)

28. juni 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • BGB-3111-306
  • 2019-000413-36 (EudraCT-nummer)
  • CTR20211594 (Registeridentifikator: ChinaDrugTrials)
  • 2023-509908-15-00 (Ctis)
  • 2023 (U.S. NIH-stipend/kontrakt)
  • 2019 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD-delingstidsramme

See plan description

Tilgangskriterier for IPD-deling

See plan description

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .